Adagio Medical (ADGM) CEO acquires 207,315 shares at $1.09 average

Rhea-AI Filing Summary

Adagio Medical Holdings, Inc. reported that its Chief Executive Officer and director acquired 207,315 shares of its common stock in an open market transaction on 12/12/2025.

The shares were purchased at a weighted average price of $1.09 per share, with individual trade prices ranging from $0.9258 to $1.14101. After this transaction, the reporting person directly owned 207,315 shares of Adagio Medical common stock.

Insider Trade Summary

Net Buyer: 207,315 shares

Net Buy 1 txn

Insider Usen Todd

Role Chief Executive Officer

Bought 207,315 shs ($226K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	207,315	$1.09	$226K

Holdings After Transaction: Common Stock — 207,315 shares (Direct)

Footnotes (2)

1. F1. Open market purchase.
2. F2. This transaction was executed in multiple trades at prices ranging from $0.9258 to $1.14101. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 12/15/2025 - 09:24 PM Learn about SEC filing dates

FAQ

What insider transaction did ADGM report in this Form 4?

The report shows that a director and Chief Executive Officer of Adagio Medical Holdings, Inc. acquired 207,315 shares of common stock on 12/12/2025 in an open market purchase.

How many Adagio Medical (ADGM) shares does the insider own after the transaction?

Following the reported transaction, the insider beneficially owned 207,315 shares of Adagio Medical common stock, held in direct ownership.

What price did the ADGM insider pay for the purchased shares?

The shares were bought at a weighted average price of $1.09 per share, with individual trades executed at prices between $0.9258 and $1.14101.

What type of transaction was reported for ADGM stock?

The transaction is coded as P and described as an open market purchase of Adagio Medical common stock.

When was the ADGM Form 4 signed?

The Form 4 was signed by /s/ Deborah Kaster, Attorney-in-Fact on 12/15/2025.

Is the reporting person an executive of Adagio Medical (ADGM)?

Yes. The reporting person is identified as both a Director and an Officer, serving as Chief Executive Officer of Adagio Medical Holdings, Inc.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Usen Todd

(Last) (First) (Middle)

C/O ADAGIO MEDICAL HOLDINGS, INC.

26051 MERIT CIRCLE, SUITE 102

(Street)

LAGUNA HILLS CA 92653

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Adagio Medical Holdings, Inc. [ ADGM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/12/2025		P(1)		207,315	A	$1.09(2)	207,315	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Open market purchase.

2. This transaction was executed in multiple trades at prices ranging from $0.9258 to $1.14101. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

	/s/ Deborah Kaster, Attorney-in-Fact	12/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.